抗β 2 糖蛋白 I IgA 在 SLICC 分类标准数据集中。

Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset.

机构信息

Department of Medicine, Alexandria University, Alexandria, Egypt.

Johns Hopkins University School of Medicine, Baltimore, MD, USA.

出版信息

Lupus. 2021 Jul;30(8):1283-1288. doi: 10.1177/09612033211014248. Epub 2021 May 6.

DOI:10.1177/09612033211014248

PMID:33957797

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10140618/

Abstract

OBJECTIVE

Anti-beta 2 glycoprotein I IgA is a common isotype of anti-beta 2 glycoprotein I in SLE. Anti-beta 2 glycoprotein I was not included in the American College of Rheumatology (ACR) SLE classification criteria, but was included in the Systemic Lupus International Collaborating Clinics (SLICC) criteria. We aimed to evaluate the prevalence of anti-beta 2-glycoprotein I IgA in SLE versus other rheumatic diseases. In addition, we examined the association between anti-beta 2 glycoprotein I IgA and disease manifestations in SLE.

METHODS

The dataset consisted of 1384 patients, 657 with a consensus physician diagnosis of SLE and 727 controls with other rheumatic diseases. Anti-beta 2 glycoprotein I isotypes were measured by ELISA. Patients with a consensus diagnosis of SLE were compared to controls with respect to presence of anti-beta 2 glycoprotein I. Among patients with SLE, we assessed the association between anti-beta 2 glycoprotein I IgA and clinical manifestations.

RESULTS

The prevalence of anti-beta 2 glycoprotein I IgA was 14% in SLE patients and 7% in rheumatic disease controls (odds ratio, OR 2.3, 95% CI: 1.6, 3.3). It was more common in SLE patients who were younger patients and of African descent (p = 0.019). Eleven percent of SLE patients had anti-beta 2 glycoprotein I IgA alone (no anti-beta 2 glycoprotein I IgG or IgM). There was a significant association between anti-beta 2 glycoprotein I IgA and anti-dsDNA (p = 0.001) and the other antiphospholipid antibodies (p = 0.0004). There was no significant correlation of anti-beta 2 glycoprotein I IgA with any of the other ACR or SLICC clinical criteria for SLE. Those with anti-beta 2 glycoprotein I IgA tended to have a history of thrombosis (12% vs 6%, p = 0.071), but the difference was not statistically significant.

CONCLUSION

We found the anti-beta 2 glycoprotein I IgA isotype to be more common in patients with SLE and in particular, with African descent. It could occur alone without other isotypes.

摘要

目的

抗β2 糖蛋白 I IgA 是 SLE 中常见的抗β2 糖蛋白 I 同种型。抗β2 糖蛋白 I 未被纳入美国风湿病学会 (ACR) SLE 分类标准，但被纳入系统性红斑狼疮国际合作临床 (SLICC) 标准。我们旨在评估抗β2 糖蛋白 I IgA 在 SLE 与其他风湿性疾病中的患病率。此外，我们还研究了抗β2 糖蛋白 I IgA 与 SLE 疾病表现之间的关联。

方法

数据集包括 1384 名患者，其中 657 名经共识性医生诊断为 SLE，727 名为其他风湿性疾病的对照。通过 ELISA 法检测抗β2 糖蛋白 I 的同种型。将 SLE 患者与对照患者进行比较，以评估抗β2 糖蛋白 I 的存在情况。在 SLE 患者中，我们评估了抗β2 糖蛋白 I IgA 与临床表现之间的关系。

结果

SLE 患者中抗β2 糖蛋白 I IgA 的患病率为 14%，风湿性疾病对照组为 7%（比值比，OR 2.3，95%CI：1.6，3.3）。它在年龄较小和非裔的 SLE 患者中更为常见（p=0.019）。11%的 SLE 患者仅有抗β2 糖蛋白 I IgA（无抗β2 糖蛋白 I IgG 或 IgM）。抗β2 糖蛋白 I IgA 与抗 dsDNA（p=0.001）和其他抗磷脂抗体（p=0.0004）之间存在显著相关性。抗β2 糖蛋白 I IgA 与 SLE 的其他 ACR 或 SLICC 临床标准均无显著相关性。抗β2 糖蛋白 I IgA 阳性的患者有血栓形成病史的倾向（12%比 6%，p=0.071），但差异无统计学意义。